NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?

Br J Dermatol. 2017 Feb;176(2):281-282. doi: 10.1111/bjd.15255.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Adalimumab*
  • Anti-Inflammatory Agents / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Hidradenitis Suppurativa / drug therapy*
  • Humans

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Adalimumab